Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.

ABSTRACT:

Introduction

Idiopathic inflammatory myopathies (IIM) represent a rare and heterogenous group diseases, and their treatment is not fully defined yet. According to previous small case series, the combination of mycophenolate mofetil (MMF) and rituximab (RTX) may be effective in controlling difficult-to-treat patients. Our aim was to further explore the efficacy and safety of this combined approach in patients with IIM.

Methods

Patients with IIM treated with the RTX/MMF combination in our Center were retrospectively identified. After the start of combination therapy, the efficacy was evaluated at 12 months (T12) according the 2016 ACR/EULAR response criteria for IIM. Cardiac imaging and pulmonary function tests were used to monitor disease activity in patients with myocarditis

SUBMITTER: Campochiaro C 

PROVIDER: S-EPMC10988925 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature